Edwards Lifesciences Corp (EW): Is This Fallen Angel Still a Good Growth Play?

Page 1 of 2

Edwards Lifesciences Corp (NYSE:EW)Healthcare stocks resemble tech stocks, in that both are eye candy to growth investors, show volatility over business cycles and thus have less appeal to value investors. Conclusively, it is important for growth investors to understand that if they pick high-growth companies with a strong market presence, they are likely to reap greater rewards during down markets than up markets. The reason is obvious. During down markets, the stronger companies will continue to grow (albeit slowly) while the weaker will be elbowed out. During up markets, even the smaller companies would show growth and rapidly catch up to the bigger ones, thus taking away a chunk of their revenues.

This discussion is premised on Edwards Lifesciences Corp (NYSE:EW)‘ present market position. As the US economy gradually expanded after the Great Recession, we saw a strong rally in Edwards. However, the momentum is now starting to break as competition is getting fiercer. Edwards Lifesciences is a medical device manufacturer and is known for its signature SAPIEN valves used to replace diseased aortic heart valves.

In spite of having a stronghold in the US, the company is starting to receive major setbacks in the European region. The company missed both earnings and revenue forecasts in the latest quarter and a selling frenzy, similar to the one seen back in October of last year, followed. The third quarter 2012 price slump, due to a revenue forecast miss, was the biggest Edwards had seen in a decade. Something similar was witnessed this past quarter, ended in April.

The bearish case

Medtronic, Inc. (NYSE:MDT) is cited as Edwards’ biggest competitor. Edwards managed to forestall Medtronic’s entry into its primary market, the US. In the latest quarter alone, Edwards Lifesciences Corp (NYSE:EW) received over $84 million from the competitor in a patent litigation. While it may have contributed toward Edwards reporting a better EPS this quarter than what it could have been otherwise, Medtronic’s Europe presence remains a huge threat to Edwards’ future performance. Adding to Edwards’ problems is the recent CE Mark approval of a valve-in-valve replacement technique using Medtronic’s CoreValve–a direct substitute to Edwards’ SAPIEN Valve. The approval is the first-of-its-kind in Europe.

Apart from Medtronic, St. Jude Medical, Inc. (NYSE:STJ) is yet another device maker causing troubles for Edwards in Europe. St. Jude’s Portico Valve received approval last year and gives EW holders another reason to worry about. And just when you think it can’t get any worse, we hear of Boston Scientific Corporation (NYSE:BSX)‘s Lotus Valve System, which is currently awaiting approval in Europe, and once approved, may send shock waves across to all competitors. Edwards management was optimistic about its move to Japan last year but competition has also crept in there.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!